FDA Slaps Clinical Hold On Iovance Biotherapeutics’ Lung Cancer Study After Patient Death – Iovance Biotherapeutics (NASDAQ:IOVA)
Wednesday, Iovance Biotherapeutics Inc IOVA announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22,…